TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991 Aug 8;325(6):398–403.
et al; Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017 Apr; 4(4):e157–e164.
TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012 Nov 15;120(20):4160–7.
DI. Disseminated intravascular coagulation in patients with solid tumors. Oncology. 2015 Feb;29(2):96–102.
CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016 Jun 2;2:16037.
CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014 Aug 14;371(7):654–66.
et al; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e495S–530S.
L Jr, Crowther
MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21;117(16):4190–207.
PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011 Jul 14;365(2):147–56.
A. Management of heparin-induced thrombocytopenia. Curr Opin Hematol. 2016 Sep;23(5):462–70.